875164-01-5

Basic information

• Product Name: (8-METHYL-4-OXOQUINAZOLIN-3(4H)-YL)ACETIC ACID
• Synonyms: (8-METHYL-4-OXOQUINAZOLIN-3(4H)-YL)ACETIC ACID;2-(8-methyl-4-oxoquinazolin-3(4H)-yl)acetic acid;2-(8-methyl-4-oxoquinazolin-3-yl)acetic acid
• CAS NO: 875164-01-5
• Molecular Formula: C11H10N2O3
• Molecular Weight: 218.21
• Mol File: 875164-01-5.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 463.9±55.0 °C(Predicted)
• Appearance: /
• Density: 1.37±0.1 g/cm3(Predicted)
• PKA: 3.65±0.10(Predicted)
• CAS DataBase Reference: (8-METHYL-4-OXOQUINAZOLIN-3(4H)-YL)ACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: (8-METHYL-4-OXOQUINAZOLIN-3(4H)-YL)ACETIC ACID(875164-01-5)
• EPA Substance Registry System: (8-METHYL-4-OXOQUINAZOLIN-3(4H)-YL)ACETIC ACID(875164-01-5)

Safety Data

• Hazardous Substances Data: 875164-01-5(Hazardous Substances Data)

Usage

General Description

(8-Methyl-4-oxoquinazolin-3(4H)-yl)acetic acid is a chemical compound with the molecular formula C11H9N3O3. It is a quinazolinone derivative and a potential bioactive compound with various pharmacological properties. This chemical has shown potential as an anti-inflammatory agent and has been studied for its potential use in the treatment of various inflammatory diseases. It has also been investigated for its potential as an analgesic and antipyretic. Additionally, it has been studied for its potential as an anticancer agent, with some research suggesting that it may have inhibitory effects on certain cancer cell lines. The compound is of interest for further research into its potential medicinal applications.

Upstream product

• 19181-54-5 8-methylquinazolin-4(3H)-one 
• 4389-45-1 3-methylantranilic acid 

Relevant articles and documents

Optimization of a Novel Quinazolinone-Based Series of Transient Receptor Potential A1 (TRPA1) Antagonists Demonstrating Potent in Vivo Activity

There has been significant interest in developing a transient receptor potential A1 (TRPA1) antagonist for the treatment of pain due to a wealth of data implicating its role in pain pathways. Despite this, identification of a potent small molecule tool possessing pharmacokinetic properties allowing for robust in vivo target coverage has been challenging. Here we describe the optimization of a potent, selective series of quinazolinone-based TRPA1 antagonists. High-throughput screening identified 4, which possessed promising potency and selectivity. A strategy focused on optimizing potency while increasing polarity in order to improve intrinisic clearance culminated with the discovery of purinone 27 (AM-0902), which is a potent, selective antagonist of TRPA1 with pharmacokinetic properties allowing for >30-fold coverage of the rat TRPA1 IC50 in vivo. Compound 27 demonstrated dose-dependent inhibition of AITC-induced flinching in rats, validating its utility as a tool for interrogating the role of TRPA1 in in vivo pain models.